Administered once weekly via subcutaneous injection, semaglutide offers efficacy and durability advantages across multiple ...
Medpage Today on MSN
Investigational GLP-1-Based Drug Hits MASH Resolution Mark, Misses Fibrosis Target
WASHINGTON -- Treatment with the investigational GLP-1/glucagon dual receptor agonist pemvidutide led to resolution of ...
Panelists discuss how subcutaneous (SubQ) drug formulations offer practical value by significantly reducing treatment times, easing staffing pressures, and enhancing efficiency in oncology practices, ...
Panelists discuss how integrating both intravenous (IV) and subcutaneous (SubQ) therapies in oncology centers requires adaptable staffing, data-driven workflow planning, and thoughtful pilot ...
If successful in the Phase III trial, VK2735 would enter direct competition with established dual agonists such as Eli ...
The MarketWatch News Department was not involved in the creation of this content.-- VYVGART(R) SC is first and only neonatal Fc receptor blocker approved to treat CIDP -- Authoriz ...
Please provide your email address to receive an email when new articles are posted on . Opdivo was previously only available intravenously. The approval comes after CHECKMATE-67T study results. Opdivo ...
With new phase 3 data backing the ability of its emergency use zalunfiban to fend off further heart damage, CeleCor ...
The drug, delivered by EMS as a single injection, improved infarct-related patency at cath lab arrival and 30-day clinical outcomes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback